AAPL350.69+8.32 (+2.43%) ▲|ABBV293.30+1.99 (+0.68%) ▲|ABT110.51+0.58 (+0.53%) ▲|ACN254.37-6.13 (-2.35%) ▼|ADBE237.32-1.98 (-0.83%) ▼|AMAT370.55+37.84 (+11.37%) ▲|AMD508.58+59.54 (+13.26%) ▲|AMGN465.23+4.81 (+1.04%) ▲|AMT189.00+0.21 (+0.11%) ▲|AMZN266.93+7.63 (+2.94%) ▲|AVGO319.48+25.79 (+8.78%) ▲|AXP324.31+3.32 (+1.03%) ▲|BA172.38-1.02 (-0.59%) ▼|BAC50.55+1.13 (+2.29%) ▲|BKNG163.49+2.83 (+1.76%) ▲|BLK1,214.71+35.84 (+3.04%) ▲|BMY62.14+0.00 (+0.00%) ▲|BNY151.23+3.51 (+2.38%) ▲|BRK-B575.25+4.36 (+0.76%) ▲|C121.97+2.92 (+2.45%) ▲|CAT598.88+40.25 (+7.21%) ▲|CL97.94+1.38 (+1.43%) ▲|CMCSA24.51+0.12 (+0.49%) ▲|COF198.58-3.29 (-1.63%) ▼|COP134.47-1.80 (-1.32%) ▼|COST1,066.18+12.62 (+1.20%) ▲|CRM214.94+1.29 (+0.60%) ▲|CSCO98.65+4.80 (+5.11%) ▲|CVS85.25+1.40 (+1.67%) ▲|CVX210.78-1.83 (-0.86%) ▼|DE691.28+19.63 (+2.92%) ▲|DHR235.12+4.87 (+2.12%) ▲|DIS119.12+2.37 (+2.03%) ▲|DUK128.10+0.32 (+0.25%) ▲|EMR169.52+7.17 (+4.42%) ▲|FDX318.84+10.70 (+3.47%) ▲|GD362.07+8.01 (+2.26%) ▲|GE335.54+12.30 (+3.81%) ▲|GEV829.34+55.23 (+7.13%) ▲|GILD169.32+2.43 (+1.46%) ▲|GM89.65+3.49 (+4.05%) ▲|GOOG286.01+2.08 (+0.73%) ▲|GOOGL288.15+3.37 (+1.18%) ▲|GS906.22+40.40 (+4.67%) ▲|HD353.42+9.95 (+2.90%) ▲|HON229.00+8.95 (+4.07%) ▲|IBM246.11+1.11 (+0.45%) ▲|INTC59.37+3.09 (+5.49%) ▲|INTU338.23-3.27 (-0.96%) ▼|ISRG460.56+7.76 (+1.71%) ▲|JNJ282.11+5.89 (+2.13%) ▲|JPM342.08+7.59 (+2.27%) ▲|KO96.03+0.36 (+0.38%) ▲|LIN520.33+5.08 (+0.99%) ▲|LLY1,411.95+57.95 (+4.28%) ▲|LMT588.19+21.11 (+3.72%) ▲|LOW232.10+7.55 (+3.36%) ▲|LRCX221.31+20.87 (+10.41%) ▲|MA655.81+3.11 (+0.48%) ▲|MCD281.44+4.92 (+1.78%) ▲|MDLZ66.44+0.42 (+0.64%) ▲|MDT102.79+0.99 (+0.97%) ▲|META641.37+31.22 (+5.12%) ▲|MMM188.63+3.48 (+1.88%) ▲|MO75.81-0.31 (-0.41%) ▼|MRK148.76+2.03 (+1.38%) ▲|MS187.10+5.66 (+3.12%) ▲|MSFT545.18+14.57 (+2.75%) ▲|MU733.15+43.15 (+6.25%) ▲|NEE86.86-0.09 (-0.10%) ▼|NFLX63.95+0.54 (+0.85%) ▲|NKE39.88+1.29 (+3.34%) ▲|NOW102.76+0.79 (+0.77%) ▲|NVDA178.67-7.97 (-4.27%) ▼|ORCL119.79+3.69 (+3.18%) ▲|PEP141.88+0.54 (+0.38%) ▲|PFE29.23-0.16 (-0.54%) ▼|PG168.32+2.92 (+1.77%) ▲|PLTR169.20+8.82 (+5.50%) ▲|PM193.12-4.76 (-2.41%) ▼|QCOM171.47+6.06 (+3.66%) ▲|RTX196.31+6.78 (+3.58%) ▲|SBUX109.44+4.03 (+3.82%) ▲|SCHW92.73+1.24 (+1.36%) ▲|SO93.57+1.23 (+1.33%) ▲|SPG233.01+4.59 (+2.01%) ▲|T21.80+0.17 (+0.79%) ▲|TMO721.63+26.87 (+3.87%) ▲|TMUS168.71+6.70 (+4.14%) ▲|TSLA378.05+19.83 (+5.54%) ▲|TXN295.73+18.37 (+6.62%) ▲|UBER71.17+2.58 (+3.76%) ▲|UNH397.62+3.47 (+0.88%) ▲|UNP297.11+0.04 (+0.01%) ▲|UPS110.96+2.66 (+2.46%) ▲|USB61.10+0.13 (+0.21%) ▲|V422.97+1.34 (+0.32%) ▲|VZ45.98-0.10 (-0.22%) ▼|WFC85.76+0.26 (+0.30%) ▲|WMT125.35-0.32 (-0.25%) ▼|XOM161.78-2.98 (-1.81%) ▼|AAPL350.69+8.32 (+2.43%) ▲|ABBV293.30+1.99 (+0.68%) ▲|ABT110.51+0.58 (+0.53%) ▲|ACN254.37-6.13 (-2.35%) ▼|ADBE237.32-1.98 (-0.83%) ▼|AMAT370.55+37.84 (+11.37%) ▲|AMD508.58+59.54 (+13.26%) ▲|AMGN465.23+4.81 (+1.04%) ▲|AMT189.00+0.21 (+0.11%) ▲|AMZN266.93+7.63 (+2.94%) ▲|AVGO319.48+25.79 (+8.78%) ▲|AXP324.31+3.32 (+1.03%) ▲|BA172.38-1.02 (-0.59%) ▼|BAC50.55+1.13 (+2.29%) ▲|BKNG163.49+2.83 (+1.76%) ▲|BLK1,214.71+35.84 (+3.04%) ▲|BMY62.14+0.00 (+0.00%) ▲|BNY151.23+3.51 (+2.38%) ▲|BRK-B575.25+4.36 (+0.76%) ▲|C121.97+2.92 (+2.45%) ▲|CAT598.88+40.25 (+7.21%) ▲|CL97.94+1.38 (+1.43%) ▲|CMCSA24.51+0.12 (+0.49%) ▲|COF198.58-3.29 (-1.63%) ▼|COP134.47-1.80 (-1.32%) ▼|COST1,066.18+12.62 (+1.20%) ▲|CRM214.94+1.29 (+0.60%) ▲|CSCO98.65+4.80 (+5.11%) ▲|CVS85.25+1.40 (+1.67%) ▲|CVX210.78-1.83 (-0.86%) ▼|DE691.28+19.63 (+2.92%) ▲|DHR235.12+4.87 (+2.12%) ▲|DIS119.12+2.37 (+2.03%) ▲|DUK128.10+0.32 (+0.25%) ▲|EMR169.52+7.17 (+4.42%) ▲|FDX318.84+10.70 (+3.47%) ▲|GD362.07+8.01 (+2.26%) ▲|GE335.54+12.30 (+3.81%) ▲|GEV829.34+55.23 (+7.13%) ▲|GILD169.32+2.43 (+1.46%) ▲|GM89.65+3.49 (+4.05%) ▲|GOOG286.01+2.08 (+0.73%) ▲|GOOGL288.15+3.37 (+1.18%) ▲|GS906.22+40.40 (+4.67%) ▲|HD353.42+9.95 (+2.90%) ▲|HON229.00+8.95 (+4.07%) ▲|IBM246.11+1.11 (+0.45%) ▲|INTC59.37+3.09 (+5.49%) ▲|INTU338.23-3.27 (-0.96%) ▼|ISRG460.56+7.76 (+1.71%) ▲|JNJ282.11+5.89 (+2.13%) ▲|JPM342.08+7.59 (+2.27%) ▲|KO96.03+0.36 (+0.38%) ▲|LIN520.33+5.08 (+0.99%) ▲|LLY1,411.95+57.95 (+4.28%) ▲|LMT588.19+21.11 (+3.72%) ▲|LOW232.10+7.55 (+3.36%) ▲|LRCX221.31+20.87 (+10.41%) ▲|MA655.81+3.11 (+0.48%) ▲|MCD281.44+4.92 (+1.78%) ▲|MDLZ66.44+0.42 (+0.64%) ▲|MDT102.79+0.99 (+0.97%) ▲|META641.37+31.22 (+5.12%) ▲|MMM188.63+3.48 (+1.88%) ▲|MO75.81-0.31 (-0.41%) ▼|MRK148.76+2.03 (+1.38%) ▲|MS187.10+5.66 (+3.12%) ▲|MSFT545.18+14.57 (+2.75%) ▲|MU733.15+43.15 (+6.25%) ▲|NEE86.86-0.09 (-0.10%) ▼|NFLX63.95+0.54 (+0.85%) ▲|NKE39.88+1.29 (+3.34%) ▲|NOW102.76+0.79 (+0.77%) ▲|NVDA178.67-7.97 (-4.27%) ▼|ORCL119.79+3.69 (+3.18%) ▲|PEP141.88+0.54 (+0.38%) ▲|PFE29.23-0.16 (-0.54%) ▼|PG168.32+2.92 (+1.77%) ▲|PLTR169.20+8.82 (+5.50%) ▲|PM193.12-4.76 (-2.41%) ▼|QCOM171.47+6.06 (+3.66%) ▲|RTX196.31+6.78 (+3.58%) ▲|SBUX109.44+4.03 (+3.82%) ▲|SCHW92.73+1.24 (+1.36%) ▲|SO93.57+1.23 (+1.33%) ▲|SPG233.01+4.59 (+2.01%) ▲|T21.80+0.17 (+0.79%) ▲|TMO721.63+26.87 (+3.87%) ▲|TMUS168.71+6.70 (+4.14%) ▲|TSLA378.05+19.83 (+5.54%) ▲|TXN295.73+18.37 (+6.62%) ▲|UBER71.17+2.58 (+3.76%) ▲|UNH397.62+3.47 (+0.88%) ▲|UNP297.11+0.04 (+0.01%) ▲|UPS110.96+2.66 (+2.46%) ▲|USB61.10+0.13 (+0.21%) ▲|V422.97+1.34 (+0.32%) ▲|VZ45.98-0.10 (-0.22%) ▼|WFC85.76+0.26 (+0.30%) ▲|WMT125.35-0.32 (-0.25%) ▼|XOM161.78-2.98 (-1.81%) ▼|
9.9 C
New York
Tuesday, November 10, 2026

Tag: officer

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

Gold Coast Health Plan Denounces Sharing of Medicaid Enrollment Data with Department of Homeland Security

CAMARILLO, Calif., June 14, 2025 /PRNewswire/ -- Gold Coast Health Plan (GCHP), the local Medi-Cal plan for Ventura County, is deeply concerned about the...

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Current Investigation Into Compass Diversified Holdings (NYSE: CODI)

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Compass Diversified Holdings (“Compass” or the “Company”) (NYSE: CODI) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws.

Ram Brand Launches ‘Never Stop Being American’ Marketing Campaign, New Brand Ethos ‘Nothing Stops Ram’

"Never Stop Being American" marketing campaign takes off across broadcast and Ram brand's social media channelsCampaign celebrates America, its people, pastimes and traditions, formally...

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1.

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response

CIVI SHAREHOLDERS: Civitas Resources, Inc. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 1 Deadline (NYSE:CIVI)

Civitas Resources, Inc. investors that lost money are notified to contact BFA Law before July 1, 2025 securities fraud class action deadline.

CenterPoint Energy reaches settlement agreement on landmark Systemwide Resiliency Plan to strengthen Houston electric system against extreme weather threats and future hazards

Largest single resiliency investment in CenterPoint history will build on Greater Houston Resiliency Initiative and help address impacts of wide range of extreme weather and...

Foundation CEO Provides Expert Testimony to U.S. Senate as Outside Witness on Vision Research Funding

Jason Menzo Urges Robust FY2026 Funding for National Eye Institute and Protection of Its Independent Status COLUMBIA, Md., June 13, 2025 /PRNewswire/ -- The Foundation Fighting...

Arbonne Unveils Innovative Plant-Powered Hair Care Collection Fueled by Scalp Science and Clinical Results

IRVINE, Calif., June 13, 2025 /PRNewswire/ -- Arbonne, a global leader in plant-powered personal care, has officially launched its new Hair Care Collection, a comprehensive...

Red White & Bloom Brands Provides Update on Status of Annual Filings

TORONTO, June 13, 2025 (GLOBE NEWSWIRE) -- Red White & Bloom Brands Inc. (CSE: RWB) (“RWB” or the “Company”) is providing an update on the status of a management cease trade order granted on May 1, 2025 (the "MCTO") by the British Columbia Securities Commission under National Policy 12-203 – Management Cease Trade Order ("NP 12-203").

Picton Mahoney Asset Management Announces Fund Name Changes, Ticker Change and Risk Rating Changes

Not for Distribution to U.S. Newswire Services or for Dissemination in the United States of America.

Franklin Electric Announces Repurchase of Company Shares

FORT WAYNE, Ind., June 13, 2025 (GLOBE NEWSWIRE) -- Franklin Electric Co., Inc. (NASDAQ: FELE) is pleased to announce the successful completion of a stock purchase transaction involving shares held within the Patricia Schaefer Settlement Trust, a trust established by the late Patricia Schaefer. The purchase transaction involved the acquisition of 1,200,000 shares of the Company’s common stock at a price equal to $86.78 per share, which was the volume-weighted average price of the stock on NASDAQ for the five trading days preceding today’s closing.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsOfficer